RECALL: Fish sold in Connecticut recalled by FDA due to bacteria concerns
Fungi concerns spark nationwide recall of Zicam and Orajel products
The recalled fish was distributed to retail locations in New York, New Jersey and Connecticut. Experts say that the product has potential to be contaminated with a bacteria called Clostridium botulinum that can cause life-threatening illness or death.
The product was likely to be repacked in deli-style or other retail packaging.
The fish is sold at Food Bazaar Supermarket in Bridgeport.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Implantica publishes Interim Report January - June 2025 (Q2)
VADUZ, Liechtenstein, Aug. 14, 2025 /PRNewswire/ -- Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum Significant events in the second quarter of 2025 FDA PMA Submission Completed - Submitted third and final module of the U.S. FDA pre-market approval (PMA) application for RefluxStop®, including responses to questions on the second module; Feedback on module 3 expected in the near-term Produced and completed initial testing on new multi-cavity production tool for RefluxStop® to support launch of manufacturing in U.S. and manage ramp-up of U.S. production (pending FDA approval) Additional preparations for U.S. market launch (pending FDA approval) included U.S. payer and reimbursement activities, finalizing new production facility of RefluxStop® in U.S. and launching our RCT (randomized clinical trial), as a heavyweight cornerstone in building global leadership in acid reflux care Positive NICE Guidance in the UK - UK's National Institute for Health and Care Excellence (NICE) issued positive guidance for the use of RefluxStop® in NHS hospitals for patients with ineffective esophageal motility (IOM/IEM), potentially transforming treatment access for millions and influencing global policy Significant events after the end of the period Landmark 5-Year Clinical Study Results - Two peer-reviewed articles were published in Surgical Endoscopy on our pivotal study results; one publication confirmed outstanding long-term safety and effectiveness outcomes, and the second publication highlighted RefluxStop®'s excellent outcomes in food passageway-related sequelae, which is common in standard of care Randomized Clinical Trial (RCT) Launch - First RCT comparing RefluxStop® with Nissen fundoplication; patient recruitment underway accumulating patients across participating hospitals. While this trial preparation led to a 20% year-on-year revenue decline for Q2, the impact is expected to ease once study recruitment stabilizes Spanish Market Expansion - Three new hospitals added, totaling 19 centers offering RefluxStop® in Spain, with a healthcare sytem receptive for new and better patient care, which is a fantastic launch since 2023 First UK National Users Meeting - Convened 21 top anti-reflux experts to discuss real-world results, operating technique and the opportunities arising from NICE's positive recommendation Financial summary second quarter 2025 Net sales decreased 22% to TEUR 433 (554) due to the launch of the randomized clinical trial with surgeons accumulating patients for the trial. Adjusted gross margin amounted to 90% (91%). Operating loss (EBIT) decreased to TEUR 4,525 (5,869). Loss after tax decreased to TEUR 5,448 (6,431). Basic and diluted loss per Class A share amounted to EUR 0.08 (0.09). Cash and short-term investments as at the end of the period of MEUR 56.3. First six months Net sales increased 2% to TEUR 1,178 (1,150). Adjusted gross margin amounted to 94% (91%). Operating loss (EBIT) decreased to TEUR 8,698 (12,956). Loss after tax decreased to TEUR 8,212 (9,903). Basic and diluted loss per Class A share amounted to EUR 0.12 (0.14). Telephone conference Implantica will hold a teleconference on 14 August 2025 at 15:00 (CEST) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast If you wish to participate via webcast, please use the following link: Dial-in Dial-in numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference. For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@ This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-08-14 08:00 CEST. About Implantica: Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop®, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information. This information was brought to you by Cision The following files are available for download: Implantica Q2 2025_ENG Implantica publishes Interim Report Jan - Jun 2025 Q2 View original content:
Business Insider
3 hours ago
- Business Insider
Soligenix receives FDA orphan designation for dusquetide
Soligenix's (SNGX) dusquetide, a treatment of Behcet's disease , received FDA orphan designation, according to a post to the agency's website. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
3 hours ago
- Yahoo
VitaMotion Introduced in 2025 as Your Healthy Back Protocol for Mobility and Comfort Support
New Two-Step Daily System Designed to Support Back Comfort, Joint Mobility, and Overall Physical Ease New York, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Disclaimer: This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and has not been evaluated by the Food and Drug Administration (FDA). VitaMotion is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician or qualified healthcare provider before beginning any new supplement, routine, or health program. Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication. Results described or implied may not be typical and should not be interpreted as guarantees. Statements made about ingredients or outcomes reflect public discussion and historical usage only, and are not endorsed by medical professionals or regulatory agencies. Always do your own research and make informed decisions. VitaMotion Launches Dual-Action Mobility and Back Health System for 2025 Wellness Demands Summary introduces a two-step program combining a nutrient-rich daily formula with a guided mobility routine developed by kinesiologist Rick Kaselj. The system is designed to address back, joint, and muscle health from both an internal and external perspective. Mobility and Back Health – A Public Health Priority Back, joint, and mobility concerns are now recognized as some of the most widespread health challenges globally. The World Health Organization reports that musculoskeletal conditions affect an estimated 1.71 billion people worldwide, making them the leading contributor to disability. The Centers for Disease Control and Prevention (CDC) estimates that one in four U.S. adults experiences chronic joint symptoms, while lower back pain consistently ranks as one of the top causes of missed workdays. The economic burden is equally significant. According to data from the Global Burden of Disease Study, musculoskeletal disorders account for hundreds of billions of dollars in healthcare costs and productivity losses annually. In workplace environments, prolonged sitting, inadequate movement breaks, and poor ergonomic setups have all been identified as contributing factors to rising cases of posture-related discomfort and reduced range of motion. This growing public health issue extends across all age groups. Aging adults face natural declines in muscle mass, bone density, and joint lubrication, but younger populations are also affected due to sedentary lifestyles. Research from the Arthritis Foundation notes that early intervention through movement and targeted nutrition can play a key role in maintaining long-term mobility. Learn more about the Rick Kaselj – Professional Background and Expertise Rick Kaselj, MS, BSc, has dedicated over 30 years to developing safe and effective mobility solutions. With a Bachelor's degree in Kinesiology from Simon Fraser University and a Master's in Exercise Science from California University of Pennsylvania, Kaselj has delivered over 315 live presentations to health and fitness professionals across North America. Throughout his career, he has specialized in bridging the gap between injury rehabilitation and functional movement. His previous work, including the widely recognized Unlock Your Hip Flexors program, has reached hundreds of thousands of people worldwide. For VitaMotion, Kaselj applied these same principles to design a concise daily mobility sequence that is adaptable for all fitness levels, requires no special equipment, and fits into a variety of environments. The Two-Step VitaMotion System VitaMotion is built around two coordinated components: Step 1 – Nutritional Support The daily powdered supplement contains nine active ingredients: magnesium, vitamin B complex, vitamin D, curcumin (from turmeric), boswellia serrata, ginger, white willow bark, L-theanine, and alpha lipoic acid. Each nutrient was selected for its documented role in supporting muscle, joint, and nerve function. Formulated without artificial fillers, dyes, or unnecessary additives, the blend is designed to be mixed with water and taken once daily, ideally in the morning when nutrient absorption can be most efficient. Step 2 – Guided Mobility Routine The 7–10 minute mobility sequence uses a 'release outer muscles first' approach. By easing surface-level muscle tension before activating deeper stabilizers, the sequence helps encourage improved alignment, posture, and range of motion. Movements are low-impact and can be performed either standing or seated, making the program accessible for individuals with varying mobility levels. Ingredient Science and Supporting Research MagnesiumEssential for muscle contraction and relaxation, magnesium supports nerve signaling and energy metabolism. The USDA has reported that low magnesium intake increases muscle fatigue and effort perception during activity. Harvard Health notes its role in flexibility and tension reduction. Vitamin B ComplexComprising eight essential vitamins, the B complex contributes to energy production and neuromuscular coordination. The Linus Pauling Institute highlights its importance in sustaining nerve health and physical endurance. Vitamin DSupports muscle performance, bone density, and balance. The NIH reports that adequate vitamin D levels can contribute to improved spine mobility and reduced risk of falls among older adults. CurcuminA bioactive compound in turmeric, curcumin has been studied for its role in supporting a healthy inflammatory response. A 2018 review in Frontiers in Pharmacology discusses its potential in maintaining mobility and joint comfort. Boswellia SerrataTraditionally used to promote joint flexibility, boswellia has been examined for its capacity to support smooth movement and overall comfort. Memorial Sloan Kettering Cancer Center provides a comprehensive overview of its uses. GingerRecognized for supporting circulation and potentially aiding in muscle performance after activity, ginger's active compounds have been the focus of both culinary and medical research. White Willow BarkHistorically valued for promoting everyday comfort, white willow bark's traditional uses are well-documented in herbal medicine literature and supported by multiple small-scale studies. L-TheanineAn amino acid naturally found in tea leaves, L-theanine supports a calm, focused state, potentially aiding natural muscle relaxation without sedation. Alpha Lipoic AcidA versatile antioxidant, alpha lipoic acid supports nerve health, energy metabolism, and cellular resilience against oxidative stress. View the full ingredient profile and program details for Why Movement and Nutrition Work Better Together Multiple studies across sports medicine, gerontology, and rehabilitation science point to the benefits of combining physical activity with targeted nutritional support. Research published in the Journal of Aging Research (2023) concluded that daily low-impact movement, when paired with specific micronutrients, can help maintain independence and functional ability in older adults. Movement stimulates blood flow, improving the delivery of nutrients to muscles and joints. At the same time, nutrients like magnesium, vitamin D, and antioxidants support the very systems that movement relies on — from neuromuscular signaling to collagen synthesis and inflammatory balance. This cyclical reinforcement may explain why integrated programs are increasingly recommended in preventive care models. Market Growth and Consumer Trends The joint health supplement industry was valued at over $11 billion in 2024, according to Grand View Research, with projections showing continued growth through 2030. The home fitness and wellness program market has followed a similar trajectory, driven by demand for convenient, adaptable solutions. Social media analytics show that hashtags such as #MobilityExercises and #BackPainRelief have collectively reached billions of views across TikTok and Instagram. Reddit communities focused on flexibility, functional training, and posture correction have seen consistent subscriber growth, with many users discussing the benefits of combining movement routines with nutritional strategies. Industry analysts anticipate that corporate wellness initiatives will increasingly integrate programs similar to VitaMotion, particularly as employers look to reduce costs associated with absenteeism and musculoskeletal claims. Lifestyle Integration was designed for versatility. Examples of integration include: Workplace Wellness: Employees can complete the seated mobility sequence during short breaks, helping offset the effects of prolonged sitting. Travel: The supplement can be packed in single-serve packets, and the routine can be done in hotel rooms without equipment. Home Use: Fits easily between household tasks or before leisure activities. Active Aging: Older adults can adapt the movements to their comfort level, maintaining independence and confidence in daily activities. Sports and Recreation: Athletes or hobbyists can use the sequence as a gentle warm-up or recovery tool. Observations from Public Data An analysis of online discussions and publicly available feedback on integrated mobility systems shows recurring themes: users are often drawn to programs that are time-efficient, require minimal space or equipment, and are supported by transparent ingredient information. Search trends indicate that consumers are more likely to adopt systems that combine educational content with practical, easy-to-follow routines. Industry reports also highlight a shift toward preventive mobility care, with growing interest in tools that address both the underlying physical structures and the nutritional factors influencing them. Future Outlook As wearable technology, AI-driven movement analysis, and ingredient traceability continue to advance, integrated systems like are expected to become even more personalized. Future iterations of such programs may include real-time posture correction, adaptive exercise progressions, and customized nutrient blends based on individual biomarker data. Public health experts anticipate that the convergence of these technologies with established exercise and nutrition science could set new standards for preventive musculoskeletal care worldwide. Contact VitaMotion – Healthy Back Protocol Email: support@ Disclaimer: This release is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Statements have not been evaluated by the Food and Drug Administration. VitaMotion is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider before starting any new supplement or movement program. Some links may lead to third-party sites. The publisher or author may receive compensation from purchases made through these links, at no extra cost to the buyer. This does not influence the content provided. Results vary. References to ingredients are based on public discussion and historical use and are not endorsements by medical professionals or regulatory agencies. CONTACT: Email: support@ in to access your portfolio
